Showing 6021-6030 of 8713 results for "".
- SkinKick Launches Acne System at Ulta Beautyhttps://practicaldermatology.com/news/skinkick-launches-acne-system-at-ulta-beauty/2460725/SkinKick’s Acne KickPRO™ Duo is the brand’s first Ulta Beauty™ exclusive. The two-step homeopathic treatment for acute acne, began rolling out in February at Ulta Beauty online and in-stores nationwide. SkinKick is a pa
- Aditxt to Initiate First In-Human Clinical Trials with its Therapeutics Programs in Psoriasishttps://practicaldermatology.com/news/aditxt-to-initiate-first-in-human-clinical-trials-with-its-therapeutics-programs-in-psoriasis/2460724/Aditx Therapeutics, Inc.’s AditxtReprogramming Therapeutics Division is preparing its to begin first-in-human clinical
- Two-Year Data Confirm Benefits, Safety of Tremfya in PsA and PsOhttps://practicaldermatology.com/news/two-year-data-confirm-benefits-safety-of-tremfya-is-psa-and-pso/2460722/Long-term data from the Phase 3 DISCOVER-2 study show continued benefit for Tremfya (guselkumab) for up to two years in adults with active psoriatic arthritis. Previous data demonstrated skin clearance, joint symptom relief, and safety for Tremfya through 24 weeks and one year (Week 52) in a
- Cetaphil Launches Sensitive Skin Awareness Weekhttps://practicaldermatology.com/news/cetaphil-launches-sensitive-skin-awareness-week/2460720/Happy Sensitive Skin Awareness Week! Sponsored by Cetaphil, the weeklong program kicks off on March 22nd and runs through March 28th. It will feature a lineup of dermatologists, influencers, and experts who wil
- Snacking on Almonds May Smooth Wrinkles, Reduce Dark Spotshttps://practicaldermatology.com/news/snacking-on-almonds-may-smooth-wrinkles-reduce-dark-spots/2460717/Snacking on almonds may help reduce wrinkles and skin pigmentation in postmenopausal women, according to a new study funded by the Almond Board of California. In this 6-month randomized controlled trial, 49 healthy postmenopausal women with Fitzpatrick skin type 1 or 2 were randomly ass
- Study: Clear Masks Improve Communication with Patientshttps://practicaldermatology.com/news/study-clear-masks-improve-communication-with-patients/2460716/Seeing really is believing. New research shows that doctors who wear transparent face masks greatly improve communication with patients compared to doctors whose faces are blocked by a standard face masks. What’s more, providers who wore the ClearMask are also perc
- With Pfizer Grant, GW Dermatology to Expand Telederm for Eczemahttps://practicaldermatology.com/news/with-pfizer-grant-gw-dermatology-to-expand-telederm-for-eczema/2460714/The George Washington University (GW) Department of Dermatology will use a $250,000 grant from Pfizer to expand accessible teledermatology for atopic dermatitis patients in Washington, DC. The dermatology team at GW, led by
- Eirion Therapeutics Closes $40M Series A Investment and Licensing Deal with Shanghai Haohai Biological Technologyhttps://practicaldermatology.com/news/eirion-therapeutics-closes-40m-series-a-investment-and-licensing-deal-with-shanghai-haohai-biological-technology/2460712/Eirion Therapeutics, Inc. closed a $40 million Series A investment and licensing deal with Shanghai Haohai Biological Technology Ltd. The deal will result in a $32 million Series A Preferred Stock investment into Eirion along with exclusive licenses that will be for all of Eir
- Differin Celebrates Retinoid Awareness Week with Educational Initiativeshttps://practicaldermatology.com/news/differin-celebrates-retinoid-awareness-week-with-educational-initiatives/2460710/Following the FDA approval of Differin Gel to be sold over the-counter in 2016, Galderma embarked on a journey to educate consumers about retinoids like adapalene. In 2017, Differin launched its first ever Retinoid Education Week to continue to drive awareness. Now in its fourth year, D
- Baricitinib Performs Well in Phase 3 AA Trialhttps://practicaldermatology.com/news/baricitinib-performs-well-in-phase-3-aa-trial/2460709/Eli Lilly and Company and Incyte’s Baricitinib is the first JAK inhibitor to demonstrate hair regrowth in a Phase 3 alopecia areata (AA) trial. Patients with severe alopecia areata who took baricitinib 2-mg or 4-mg once daily showed a statistically significant improvemen